Generic Medicine Info
Indications and Dosage
Irritable bowel syndrome
Adult: 100-200 mg tid.
May be taken with or without food.
Reconstitute the granules in the provided bottle by adding water up to the designated mark then shake the bottle to mix. Refer to specific product guidelines for appropriate instructions on reconstitution.
Special Precautions
Pregnancy and lactation.
Adverse Reactions
Significant: CNS depression.
Nervous system disorders: Presyncope/syncope.
Skin and subcutaneous tissue disorders: Rash.
Psychiatric disorders: Mood change.
Patient Counseling Information
This drug may impair physical and mental abilities, if affected, do not drive or operate machinery.
Description: Trimebutine is a gastrointestinal motility modifier. It promotes intestinal motility by triggering phase-III waves produced by the migrating motor complex, it also inhibits motility in the occurrence of prior stimulation.
Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1-2 hours.
Excretion: Mainly via urine (70%); faeces (5-12%). Elimination half-life: Approx 10-12 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 5573, Trimebutine. Accessed July 28, 2021.

Store below 30°C.
MIMS Class
GIT Regulators, Antiflatulents & Anti-Inflammatories
ATC Classification
A03AA05 - trimebutine ; Belongs to the class of synthetic anticholinergics, esters with tertiary amino group. Used in the treatment of functional bowel disorders.
Anon. Trimebutine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 09/07/2021.

Buckingham R (ed). Trimebutine Maleate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 09/07/2021.

Disclaimer: This information is independently developed by MIMS based on Trimebutine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in